Cadence Biomedical Receives Phase I Award from National Institutes of Health
Seattle, WA (September 26, 2011) – Cadence Biomedical, a provider of medical devices that help people with severe disabilities walk, has been awarded a Phase I STTR grant worth up to $254,000 from the National Institute on Minority Health and Health Disparities for research aimed at developing a kinetic prosthesis to improve mobility for transfemoral amputees. Brian Glaister, Cadence’s CEO, is the principle investigator for this project.
Titled “An Exotendon Prosthesis to Improve Walking for Lower Limb Amputees,” this award provides one-year funding to adapt Cadence’s kinetic orthosis into a prosthesis for above-knee amputees. “We are honored to have received this award,” said Brian Glaister. “Receiving NIH funding is a significant accomplishment, and we’re very thankful to be able to use these funds to expand our product offerings and help more people with disabilities walk.”
About 40% of all lower limb amputees are unable to walk with a prosthesis, in part due to the enormous inefficiencies associated with prosthetic gait. This project will leverage Cadence’s kinetic orthosis technology, which uses a proprietary tuned system of cams and springs to provide stability and movement assistance to weakened muscles without the use of powered mechanisms. The kinetic orthosis technology has been able to improve mobility for people with multiple sclerosis, spinal cord injuries, stroke, and other conditions. With this project, Cadence seeks develop a new product to improve mobility for above-knee amputees as well.
Cadence Biomedical is a privately held early stage medical device company whose mission is to improve mobility for people with disabilities. The company’s flagship kinetic orthosis product is a revolutionary device that can provide assistance to muscles and help people with severe disabilities walk. Cadence is headquartered in Seattle, WA. For more information, please visit www.cadencebiomedical.com.